Loading...
•
Jun 30, 2025
Jaguar Health Q2 2025 Earnings Report
Jaguar Health reported Q2 2025 results with $3.0 million in revenue, up 35% from Q1, and strong performance from prescription products including Mytesi.
Key Takeaways
Jaguar Health delivered approximately $3.0 million in Q2 2025 revenue, driven by strength in its prescription products portfolio. Despite the revenue increase, the company posted a net loss of $10.4 million and an operating loss of $8.0 million. Mytesi prescriptions rose 6.5% sequentially, and licensing revenues added modest contributions.
Net revenue for Q2 2025 was approximately $3.0 million, up 35% QoQ.
Net loss was $10.4 million, or $(10.25) per share.
Mytesi prescription volume increased 6.5% vs. Q1 2025.
Non-GAAP recurring EBITDA was a loss of $7.9 million, improved from $8.8 million YoY.
Forward Guidance
Jaguar Health plans to pursue licensing partnerships and regulatory progress for crofelemer, with expectations for non-dilutive funding and continued prescription growth.
Positive Outlook
- Mytesi prescription volume grew 6.5% QoQ.
- Crofelemer trials in rare disease settings show early promise.
- License fee revenue contributed positively.
- Company is pursuing non-dilutive licensing deals.
- Non-GAAP recurring EBITDA loss narrowed YoY.
Challenges Ahead
- Net loss widened to $10.4 million.
- Operating loss increased to $8.0 million.
- Cost of product revenue rose with increased Mytesi sales.
- Sales & marketing expenses increased $1.0 million YoY.
- G&A expenses rose due to legal and compliance costs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...